A Novel Breath Actuated Device (Autohaler™) Consistently Actuates During the Early Phase of Inspiration

Marshik, Patricia; Larsen, Julie S.; Leach, Chet; Halverson, Philip; Ekholm, Bruce P.; Amies, Mark; Kaiser, Harold B.; Weisberg, Stephen C.; Sellers, Judith

doi:10.1089/jam.1995.8.187

Cited by 10 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Zusatzstoffen [3]. Um mögliche Schwierigkeiten in der Koordination von Auslösung und Inspira− tion zu verhindern, setzen einige pMDI das Aerosol atemzugge− steuert bei Beginn der Inspiration frei [4,5]. Pulverinhalatoren (dry powder inhalers, DPI) verwenden keine Treibmittel.…”

Section: Einleitung !unclassified

Schulung des Inhalationsmanövers bei Kindern mit Asthma bronchiale mittels optischem Feedback

Kamin¹,

Kreplin²

2007

Pneumologie

View full text Add to dashboard Cite

show abstract

Section: Einleitung !unclassified

Schulung des Inhalationsmanövers bei Kindern mit Asthma bronchiale mittels optischem Feedback

Kamin¹,

Kreplin²

2007

Pneumologie

View full text Add to dashboard Cite

show abstract

“…HFA-BDP is available as a press and breathe pMDI or as the Autohaler TM inhalation device (HFA-BDP AH), a breath-actuated MDI that is activated at normal resting inspiratory flow rates [9, 10, 11]. HFA-BDP AH has been shown to be of clinical benefit to patients with problems handling a press and breathe pMDI [12].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Hydrofluoroalkane-Beclomethasone Dipropionate Autohaler<sup>TM</sup> with Budesonide Turbuhaler<sup>TM</sup> in Asthma Control

Worth

Jf²,

Pieters³

2001

Respiration

View full text Add to dashboard Cite

Background: Hydrofluoroalkane-beclomethasone dipropionate Autohaler^TM (HFA-BDP AH) is a breath-actuated chlorofluorocarbon (CFC)-free metered dose inhaler in which BDP is in a solution of HFA propellant. Budesonide Turbuhaler^TM (BUD TH) is a breath-dependent dry powder inhaler. Objectives: To test the hypothesis that half the daily dose of HFA-BDP AH would provide an equivalent control of asthma symptoms to the BUD TH. Methods: This was an 8-week open study in patients with symptomatic moderate-to-severe asthma, previously on BUD 500–1,000 µg day^–1, or an equivalent. After 5–14 days’ run-in, patients were randomized to HFA-BDP AH 800 µg day^–1 or BUD TH 1,600 µg day^–1. The intent-to-treat population consisted of 111 patients on HFA-BDP AH and 98 patients on BUD TH. Results: Mean change from baseline in PEF in the morning (AM PEF) at week 8 was 23.95 liters min^–1 for HFA-BDP AH and 24.46 liters min^–1 for BUD TH. A two-sided equivalence test using the 0.51 liter min^–1 difference gave 95% confidence intervals within a defined equivalence interval of (–∞, 25 liters min^–1) indicating that the mean change in AM PEF was equivalent for the two groups. There were no significant differences in the mean change from baseline in FEV₁ or β-agonist use. Patients using HFA-BDP AH had a significantly greater mean change from baseline in the percentage of days free from shortness of breath (p = 0.05), chest tightness (p = 0.02) and nights without sleep disturbance (p = 0.04) at week 3, and wheeze (p = 0.01), shortness of breath (p = 0.02), chest tightness (p < 0.01) and daily asthma symptoms (p = 0.03) at week 8. The incidence, type and severity of adverse events were similar in each group. At week 8, the mean change from baseline in corrected urine cortisol/creatinine ratio in a subgroup of patients was –0.36 for HFA-BDP and –4.88 for BUD TH (p < 0.01). Conclusions: HFA-BDP 800 µg day^–1 provided control of moderate-to-severe asthma with efficacy and safety at least similar to BUD TH 1,600 µg day^–1.

show abstract

Pharmacokinetic comparison of beclomethasone dipropionate extrafine aerosol from two inhaler devices in children with asthma

Harrison

Kurup

Chen

et al. 2002

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

A Novel Breath Actuated Device (Autohaler™) Consistently Actuates During the Early Phase of Inspiration

Abstract: The AH consistently actuates early during inspiration, which is considered the optimal time for drug delivery, regardless of the canister life.

Cited by 10 publications

References 5 publications

Schulung des Inhalationsmanövers bei Kindern mit Asthma bronchiale mittels optischem Feedback

Schulung des Inhalationsmanövers bei Kindern mit Asthma bronchiale mittels optischem Feedback

Comparison of Hydrofluoroalkane-Beclomethasone Dipropionate Autohaler<sup>TM</sup> with Budesonide Turbuhaler<sup>TM</sup> in Asthma Control

Pharmacokinetic comparison of beclomethasone dipropionate extrafine aerosol from two inhaler devices in children with asthma

Contact Info

Product

Resources

About